The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer

Klaus Pantel; Catherine Alix-Panabières

doi:10.1158/2159-8290.CD-12-0432

The potential of circulating tumor cells as a liquid biopsy to guide therapy in prostate cancer

Cancer Discov. 2012 Nov;2(11):974-5. doi: 10.1158/2159-8290.CD-12-0432. Epub 2012 Oct 23.

Authors

Klaus Pantel¹, Catherine Alix-Panabières

Affiliation

¹ Department of Tumour Biology, Centre of Experimental Medicine, University Cancer Center Hamburg, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany. pantel@uke.uni-hamburg.de

PMID: 23093252
DOI: 10.1158/2159-8290.CD-12-0432

Abstract

Miyamoto and colleagues present data that prostate-specific antigen/prostate-specific membrane antigen (PSA/PSMA)-based measurements of androgen receptor (AR) signaling in circulating tumor cells (CTC) enable real-time quantitative monitoring of intratumoral AR signaling. This finding indicates that measuring AR signaling within CTCs may help to guide therapy in metastatic prostate cancer and highlights the use of CTCs as liquid biopsy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

Biomarkers, Tumor / metabolism*
Humans
Male
Neoplasms, Hormone-Dependent / metabolism*
Neoplastic Cells, Circulating / metabolism*
Prostatic Neoplasms / metabolism*
Receptors, Androgen / metabolism*

Substances

Biomarkers, Tumor
Receptors, Androgen